Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001127602-25-015917
Filing Date
2025-05-29
Accepted
2025-05-29 17:23:41
Documents
1
Period of Report
2025-05-20

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT form3.html 3  
1 PRIMARY DOCUMENT form3.xml 3 1983
  Complete submission text file 0001127602-25-015917.txt   3694
Mailing Address 251 BALLARDVALE ST WILMINGTON MA 01887
Business Address 251 BALLARDVALE ST WILMINGTON MA 01887 781-222-6000
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Issuer) CIK: 0001100682 (see all company filings)

EIN.: 061397316 | Fiscal Year End: 1227
SIC: 8731 Services-Commercial Physical & Biological Research
(CF Office: 08 Industrial Applications and Services)

Mailing Address C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO CA 92121
Business Address
Enyedy Mark J (Reporting) CIK: 0001586965 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-15943 | Film No.: 251004879